Stuart Therapeutics completed a Phase 3 trial for ST-100, a treatment for dry eye disease, involving a randomized, ...

Linsitinib showed significant efficacy in reducing proptosis in TED patients, with a 52% responder rate at 150mg BID. The ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Andrew G. Lee, MD, and Andrew Carey, MD, return for this latest episode of the NeuroOp Guru to discuss whether a dead nerve ...

The iDose platform is designed to address ubiquitous patient non-adherence and chronic side effects associated with topical ...

New features include simultaneous calculation for both eyes, access to toric and non-toric results, and improved theater view design.

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Panelists discuss how successful implementation of the port delivery system requires careful attention to surgical technique ...

Panelists discuss how patients experiencing a high treatment burden with frequent anti-VEGF injections every 4-8 weeks are optimal candidates for the port delivery system, which can help reduce their ...